Xilio Therapeutics (Xilio Therapeutics) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Xilio Therapeutics Change In Inventory?

Xilio Therapeutics's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Xilio Therapeutics's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Xilio Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Xilio Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Xilio Therapeutics's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Xilio Therapeutics Change In Inventory Historical Data

The historical data trend for Xilio Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xilio Therapeutics Change In Inventory Chart

Xilio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Xilio Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial												-	-	-	-	-

Xilio Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Xilio Therapeutics (NAS:XLO) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Xilio Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Xilio Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Xilio Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Xilio Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Xilio Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Xilio Therapeutics (Xilio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xilio Therapeutics Inc (NAS:XLO) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Winter Street, Suite 300, Waltham, MA, USA, 02451

Website

https://www.xiliotx.com

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index.

Executives

Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Katarina Luptakova	officer: Chief Medical Officer	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Christopher James Frankenfield	officer: Chief Operating Officer	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Kevin M. Brennan	officer: SVP, FINANCE AND ACCOUNTING	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Edward C English	officer: Principal Accounting Officer	828 WINTER STREET, WALTHAM MA 02451
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Robert W. Ross	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Yuan Xu	director	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Bain Capital Life Sciences Fund Ii, L.p.	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Atlas Venture Opportunity Fund I, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Sv7 Impact Medicine Fund Lp	10 percent owner	71 KINGSWAY, LONDON X0 WC2B 6ST
Bcls Ii Investo (gp), Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investco, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Investors Ii, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Rivervest Venture Fund Iv, L.p.	10 percent owner	101 SOUTH HANLEY ROAD, SUITE 1850, ST. LOUIS MO 63105